Following a comprehensive review of safety and toxicology data by an independent panel of scientists of international repute convened by Soni & Associates Inc, Sabinsa’s patented colour-free Curcumin C3 Reduct tetrahydrocurcuminoids, a metabolite of curcumin, has been found to meet criteria as Generally Recognised As Safe (GRAS) as per FDA’s scientific procedures.
“In coming to the conclusion that C3 Reduct, a standardised extract obtained by hydrogenation of the curcuminoids from the rhizomes of the Curcuma longa (turmeric) is GRAS, the panel critically evaluated the publicly available data, manufacturing process, specifications, intended use levels, and other information summarised in the GRAS dossier,” Madhusudan Soni, who convened the scientific team, wrote in the report. “The panel considered that the available qualitative and quantitative scientific evidence, including human and animal data, to be sufficient to establish the safety of C3 Reduct at maximum levels for various foods and beverages, resulting in the 90th percentile all-user estimated intake of 239.20 mg/person/day.”
Soni continued to explain that the safety assessment to assign GRAS status for C3 Reduct for the specified food uses means it must meet FDA criteria for reasonable certainty of no harm by considering both the technical and common knowledge elements.
The most clinically studied curcumin brand, Curcumin C3 Complex, received a GRAS ‘Letter of No Objection’ in October 2013, and C3 Reduct was designed to deliver the benefits of Sabinsa’s flagship product, but without the vivid colour inherent in turmeric extracts. Its colourless attribute makes it ideal for use in food and beverage products.
“We’re pleased to have this independent verification that C3 Reduct is safe for use in foods and beverages, particularly given the strong demand of the benefits of curcumin among consumers,” said N Kalyanam, Sabinsa’s President of R&D.
